In vitro effects of ursolic acid on RANKL-induced osteoclast differentiation
Öz
Purpose: Ursolic acid is a small pentacyclic triterpene molecule composed of isoprenoid units. Although ursolic acid has been shown to be effective in the treatment of rheumatoid arthritis in many studies, very little research has been conducted on bone diseases caused by bone loss. The present study aimed to evaluate the effects of ursolic acid on osteoclast formation with the aim of finding herbal medicines that inhibit osteoclast function to strengthen bones and promote vitality in old age.
Materials and Methods: RAW264.7 murine macrophages were used in our study and cells were treated with 100 ng/mL RANKL for osteoclastic differentiation. The effects of ursolic acid treatment on cell viability, tartrate-resistant acid phosphatase (TRAP) formation and osteoclastic gene expression levels were then measured.
Results: Our results showed that ursolic acid did not exhibit significant cytotoxicity (3.2-9.8%) at concentrations of 2.5-10 µg/mL. Furthermore, ursolic acid inhibited osteoclast differentiation (15.2-39.1%) and suppressed the expression of osteoclastic genes such as cathepsin K (3.8-22.3%), TRAP (16.3-48. 7%), matrix metalloproteinase-9 (MMP-9) (10.7-40.2%), nuclear factor of activated T-cell cytoplasmic 1 (NFATc1) (1.2-29.7%), c-Fos (0.9-13.8%) and microphthalmia-associated transcription factor (MITF) (2.2-21.6%).
Conclusion: Ursolic acid has been shown to inhibit RANKL-induced osteoclast differentiation and therefore we believe that ursolic acid may be used for the treatment and prevention of osteoporosis.
Anahtar Kelimeler
Ursolic acid, RAW264.7 macrophages, osteoporosis, osteoclast, RANKL
Destekleyen Kurum
This research was financially supported in part by the Office of Scientific Research Projects of Van Yuzuncu Yil University under Grant number (TLO-2023-10609).
Proje Numarası
TLO-2023-10609
Etik Beyan
As this research is a cell culture study, ethics committee approval is not required. No conflict of interest was declared by the authors.
Kaynakça
- Yedavally-Yellayi S, Ho AM, Patalinghug EM. Update on osteoporosis. Prim Care. 2019;46:175-90.
- Gardner MJ, Collinge C. Management principles of osteoporotic fractures. Injury. 2016;47:33-5.
- Buck HV, Stains JP. Osteocyte-mediated mechanical response controls osteoblast differentiation and function. Front Physiol. 2024;15:1364694.
- Takegahara N, Kim H, Choi Y. Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases. Exp Mol Med. 2024;56:264-72.
- Anwar A, Sapra L, Gupta N, Ojha RP, Verma B, Srivastava RK. Fine-tuning osteoclastogenesis: an insight into the cellular and molecular regulation of osteoclastogenesis. J Cell Physiol. 2023;238:1431-64.
- Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17-25.
- Feng X. RANKing intracellular signaling in osteoclasts. IUBMB Life. 2005;57:389-95.
- Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457-75.
- Kodama J, Kaito T. Osteoclast multinucleation: Review of current literature. Int J Mol Sci. 2020;21:5685.
- Soysa NS, Alles N. NF-kappaB functions in osteoclasts. Biochem Biophys Res Commun. 2009;378:1-5.
